Cargando…

Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau

BACKGROUND: Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age, but studies have shown that an additional dose before 9 months of age might have beneficial nonspecific effects. Within a randomized trial designed to examine nonspecific effects of early MV receipt on mortality,...

Descripción completa

Detalles Bibliográficos
Autores principales: Do, Vu An, Biering-Sørensen, Sofie, Fisker, Ane Bærent, Balé, Carlito, Rasmussen, Stine Møller, Christensen, Lone Damkjær, Jensen, Kristoffer Jarlov, Martins, Cesário, Aaby, Peter, Benn, Christine Stabell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441109/
https://www.ncbi.nlm.nih.gov/pubmed/28077730
http://dx.doi.org/10.1093/infdis/jiw512
_version_ 1783238198961373184
author Do, Vu An
Biering-Sørensen, Sofie
Fisker, Ane Bærent
Balé, Carlito
Rasmussen, Stine Møller
Christensen, Lone Damkjær
Jensen, Kristoffer Jarlov
Martins, Cesário
Aaby, Peter
Benn, Christine Stabell
author_facet Do, Vu An
Biering-Sørensen, Sofie
Fisker, Ane Bærent
Balé, Carlito
Rasmussen, Stine Møller
Christensen, Lone Damkjær
Jensen, Kristoffer Jarlov
Martins, Cesário
Aaby, Peter
Benn, Christine Stabell
author_sort Do, Vu An
collection PubMed
description BACKGROUND: Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age, but studies have shown that an additional dose before 9 months of age might have beneficial nonspecific effects. Within a randomized trial designed to examine nonspecific effects of early MV receipt on mortality, we conducted a substudy to investigate the effect of early MV receipt on morbidity. METHODS: Children were randomly assigned at a ratio of 2:1 to receive 2 doses of MV at 18 weeks and age 9 months (intervention group) or 1 dose of MV at age 9 months, in accordance with current practice (control group). Children were visited weekly from enrollment to age 9 months; the mother reported morbidity, and the field assistants examined the children. Using Cox and binomial regression models, we compared the 2 randomization groups. RESULTS: Among the 1592 children, early measles vaccination was not associated with a higher risk of the well-known adverse events of fever, rash, and convulsions within the first 14 days. From 15 days after randomization to age 9 months, early measles vaccination was associated with reductions in maternally reported diarrhea (hazard ratio [HR], 0.89; 95% confidence interval [CI], .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and fever (HR, 0.93; 95% CI, .87–1.00). CONCLUSION: Early MV receipt was associated with reduced general morbidity in the following months, supporting that early MV receipt may improve the general health of children.
format Online
Article
Text
id pubmed-5441109
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54411092017-05-30 Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau Do, Vu An Biering-Sørensen, Sofie Fisker, Ane Bærent Balé, Carlito Rasmussen, Stine Møller Christensen, Lone Damkjær Jensen, Kristoffer Jarlov Martins, Cesário Aaby, Peter Benn, Christine Stabell J Infect Dis Major Article BACKGROUND: Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age, but studies have shown that an additional dose before 9 months of age might have beneficial nonspecific effects. Within a randomized trial designed to examine nonspecific effects of early MV receipt on mortality, we conducted a substudy to investigate the effect of early MV receipt on morbidity. METHODS: Children were randomly assigned at a ratio of 2:1 to receive 2 doses of MV at 18 weeks and age 9 months (intervention group) or 1 dose of MV at age 9 months, in accordance with current practice (control group). Children were visited weekly from enrollment to age 9 months; the mother reported morbidity, and the field assistants examined the children. Using Cox and binomial regression models, we compared the 2 randomization groups. RESULTS: Among the 1592 children, early measles vaccination was not associated with a higher risk of the well-known adverse events of fever, rash, and convulsions within the first 14 days. From 15 days after randomization to age 9 months, early measles vaccination was associated with reductions in maternally reported diarrhea (hazard ratio [HR], 0.89; 95% confidence interval [CI], .82–.97), vomiting (HR, 0.86; 95% CI, .75–.98), and fever (HR, 0.93; 95% CI, .87–1.00). CONCLUSION: Early MV receipt was associated with reduced general morbidity in the following months, supporting that early MV receipt may improve the general health of children. Oxford University Press 2017-04-15 2017-01-11 /pmc/articles/PMC5441109/ /pubmed/28077730 http://dx.doi.org/10.1093/infdis/jiw512 Text en © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, contact journals.permissions@oup.com.
spellingShingle Major Article
Do, Vu An
Biering-Sørensen, Sofie
Fisker, Ane Bærent
Balé, Carlito
Rasmussen, Stine Møller
Christensen, Lone Damkjær
Jensen, Kristoffer Jarlov
Martins, Cesário
Aaby, Peter
Benn, Christine Stabell
Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau
title Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau
title_full Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau
title_fullStr Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau
title_full_unstemmed Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau
title_short Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau
title_sort effect of an early dose of measles vaccine on morbidity between 18 weeks and 9 months of age: a randomized, controlled trial in guinea-bissau
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441109/
https://www.ncbi.nlm.nih.gov/pubmed/28077730
http://dx.doi.org/10.1093/infdis/jiw512
work_keys_str_mv AT dovuan effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT bieringsørensensofie effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT fiskeranebærent effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT balecarlito effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT rasmussenstinemøller effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT christensenlonedamkjær effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT jensenkristofferjarlov effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT martinscesario effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT aabypeter effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau
AT bennchristinestabell effectofanearlydoseofmeaslesvaccineonmorbiditybetween18weeksand9monthsofagearandomizedcontrolledtrialinguineabissau